Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Goettingen, Göttingen, Germany.
Department of Biotechnology, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Med Oncol. 2023 Jun 18;40(7):207. doi: 10.1007/s12032-023-02074-x.
Microbes have an immense metabolic capability and can adapt to a wide variety of environments; as a result, they share complicated relationships with cancer. The goal of microbial-based cancer therapy is to treat patients with cancers that are not easily treatable, by using tumor-specific infectious microorganisms. Nevertheless, a number of difficulties have been encountered as a result of the harmful effects of chemotherapy, radiotherapy, and alternative cancer therapies, such as the toxicity to non-cancerous cells, the inability of medicines to penetrate deep tumor tissue, and the ongoing problem of rising drug resistance in tumor cells. Due to these difficulties, there is now a larger need for designing alternative strategies that are more effective and selective when targeting tumor cells. The fight against cancer has advanced significantly owing to cancer immunotherapy. The researchers have greatly benefited from their understanding of tumor-invading immune cells as well as the immune responses that are specifically targeted against cancer. Application of bacterial and viral cancer therapeutics offers promising potential to be employed as cancer treatments among immunotherapies. As a novel therapeutic strategy, microbial targeting of tumors has been created to address the persisting hurdles of cancer treatment. This review outlines the mechanisms by which both bacteria and viruses target and inhibit the proliferation of tumor cells. Their ongoing clinical trials and possible modifications that can be made in the future have also been addressed in the following sections. These microbial-based cancer medicines have the ability to suppress cancer that builds up and multiplies in the tumor microenvironment and triggers antitumor immune responses, in contrast to other cancer medications.
微生物具有巨大的代谢能力,可以适应各种各样的环境;因此,它们与癌症有着复杂的关系。基于微生物的癌症治疗的目标是通过使用肿瘤特异性传染性微生物来治疗那些难以治疗的癌症患者。然而,由于化疗、放疗和替代癌症治疗(如对非癌细胞的毒性、药物无法穿透深部肿瘤组织以及肿瘤细胞不断出现的耐药性问题)的有害影响,遇到了许多困难。由于这些困难,现在更需要设计更有效和更有针对性的替代策略来靶向肿瘤细胞。癌症免疫疗法使癌症的治疗取得了重大进展。研究人员从对肿瘤浸润免疫细胞以及针对癌症的特异性免疫反应的理解中受益匪浅。细菌和病毒癌症疗法的应用为癌症治疗提供了有希望的潜力,成为免疫疗法中的一种选择。作为一种新的治疗策略,已经开发出了针对肿瘤的微生物靶向治疗方法,以解决癌症治疗中持续存在的障碍。这篇综述概述了细菌和病毒靶向和抑制肿瘤细胞增殖的机制。在接下来的部分中,还讨论了它们正在进行的临床试验和未来可能进行的修改。与其他癌症药物不同,这些基于微生物的癌症药物能够抑制在肿瘤微环境中积聚和增殖的癌症,并触发抗肿瘤免疫反应。